(Q30383172)

21 June 2017

title

EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). (English)

1 reference

hand, foot and mouth disease

21 June 2017

1 reference

1 reference

Qun-ying Mao

1

1 reference

21 June 2017

Yiping Wang

2

1 reference

21 June 2017

Lianlian Bian

3

1 reference

21 June 2017

Miao Xu

4

1 reference

21 June 2017

Zhenglun Liang

5

1 reference

21 June 2017

publication date

6 January 2016

1 reference

Expert Review of Vaccines

21 June 2017

published in

1 reference

21 June 2017

volume

15

1 reference

21 June 2017

issue

5

1 reference

21 June 2017

page(s)

599-606

1 reference

Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Enterovirus 71 infection: An experience in Korea, 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Emerging human papillomavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

A review of clinical trials of human papillomavirus prophylactic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

An inactivated enterovirus 71 vaccine in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Characterization of the enterovirus 71 VP1 protein as a vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

EV71 vaccine, an invaluable gift for children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Review of enterovirus 71 vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Production of EV71 vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Immunological evaluation and comparison of different EV71 vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Hand, foot, and mouth disease in China, 2008-12: an epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Next generation dengue vaccines: a review of candidates in preclinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

21 January 2018

Enterovirus 71 in Taiwan

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

An outbreak of hand, foot and mouth disease in Bhubaneswar, Odisha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Hand, foot and mouth disease in Guangdong, China, in 2013: new trends in the continuing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Epidemic characteristics of hand, foot, and mouth disease in southern China, 2013: coxsackievirus A6 has emerged as the predominant causative agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Enterovirus spectrum from the active surveillance of hand foot and mouth disease patients under the clinical trial of inactivated Enterovirus A71 vaccine in Jiangsu, China, 2012-2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Is a multivalent hand, foot, and mouth disease vaccine feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Comparison of clinical features between coxsackievirus A2 and enterovirus 71 during the enterovirus outbreak in Taiwan, 2008: a children's hospital experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Prevalence and characterization of enterovirus infections among pediatric patients with hand foot mouth disease, herpangina and influenza like illness in Thailand, 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

An outbreak of Kingella kingae infections associated with hand, foot and mouth disease/herpangina virus outbreak in Marseille, France, 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Animal models of enterovirus 71 infection: applications and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Update on enterovirus 71 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Virus-like particles as immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Virus-like particles: flexible platforms for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1138862

10.1586/14760584.2016.1138862

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference